Yamamoto, Maeri http://orcid.org/0000-0002-5239-6225
Inada, Toshiya http://orcid.org/0000-0002-8427-5639
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP21K07498)
Article History
Received: 31 August 2022
Accepted: 28 November 2022
First Online: 8 December 2022
Declarations
:
: The authors declare that they have no competing financial interests. The authors contacted the drug information offices of pharmaceutical companies (namely, Jansen, Lilly, and Shionogi) in Japan that market drugs for ADHD (namely, methylphenidate hydrochloride, atomoxetine hydrochloride, guanfacine hydrochloride, and lisdexamfetamine mesylate) to check whether they have any literature reporting PET studies in patients with ADHD and received information from them.
: Not applicable. This is a review article. No human or animal studies were conducted for this manuscript.